Я проверял по местам публикаций в обязательных изданиях международных. Ноль.
In an observational registry-based study from 169 hospitals across Asia (AS), Europe (EU), Africa (AF), North (NA) and South America (SA), we evaluated critically ill hospitalized patients diagnosed with COVID-19 with lung injury requiring mechanical ventilation, between January 1st 2020 and March 1st 2020. In this series of 1,970 patients, 1,609 survived hospitalization to discharge and 361 died (18.3%). We recorded 52 patients (AS-7, EU-21, AF-3, NA-14, SA-7) who received Ivermectin (150 mcg/Kg) once after mechanical ventilation was instituted. The indications for use of the drug were related to clinician preference and based on prior data on the broad antimicrobial and specifically antiviral effects of this agent. Compared to 1,918 conventionally treated patients we observed a survival benefit for ivermectin (mortality rate 18.6% vs 7.7%; HR 0.18, 95% CI (0.07-0.48), log rank (Mantel-Cox) p<0.001). The hospital length of stay was 15.7 +/- 8.1 days vs 10.9 +/- 6.1 days, p<0.001 and intensive care unit length of stay 8.2 +/- 6.2 days vs 6.0 +/- 3.9 days, p<0.001 respectively.